SLC5A2 and type 2 diabetes mellitus: Since, as occurs in a small percentage of type 1 diabetic patients, she was C-peptide positive (indicating residual endogenous insulin production) it was hypothesized that her glycemic control could be maintained or even improved on the combination of a basal insulin and an SGLT2 inhibitor without utilizing a short-acting insulin as has been documented to occur in patients with type 2 diabetes [6].